Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review
Authors:
- Eveline P. van PoelgeestEPEveline P. van Poelgeest
- On behalf of the EUGMS Task & Finish group on Fall-risk-increasing drugsODOn behalf of the EUGMS Task & Finish group on Fall-risk-increasing drugs
Open Access
- 3 February 2023
- journal article
- research article
- Published by Springer Nature in European Geriatric Medicine
- Vol. 14 (4) , 659-674
Abstract
Purpose: Both heart failure and its treatment with diuretics or SGLT2 inhibitors increase fall risk in older adults. Therefore, decisions to continue or deprescribe diuretics or SGLT2 inhibitors in older heart failure patients who have fallen are generally highly complex and challenging for clinicians. However, a comprehensive overview of information required for rationale and safe decision-making is lacking. The aim of this clinical review was to assist clinicians in safe (de)prescribing of these drug classes in older heart failure patients. Methods: We comprehensively searched and summarized published literature and international guidelines on the efficacy, fall-related safety issues, and deprescribing of the commonly prescribed diuretics and SGLT2 inhibitors in older adults. Results: Both diuretics and SGLT2 inhibitors potentially cause various fall-related adverse effects. Their fall-related side effect profiles partly overlap (e.g., tendency to cause hypotension), but there are also important differences; based on the currently available evidence of this relatively new drug class, SGLT2 inhibitors seem to have a favorable fall-related adverse effect profile compared to diuretics (e.g., low/absent tendency to cause hyperglycemia or electrolyte abnormalities, low risk of worsening chronic kidney disease). In addition, SGLT2 inhibitors have potential beneficial effects (e.g., disease-modifying effects in heart failure, renoprotective effects), whereas diuretic effects are merely symptomatic. Conclusion: (De)prescribing diuretics and SGLT2 inhibitors in older heart failure patients who have fallen is often highly challenging, but this clinical review paper assists clinicians in individualized and patient-centered rational clinical decision-making: we provide a summary of available literature on efficacy and (subclass-specific) safety profiles of diuretics and SGLT2 inhibitors, and practical guidance on safe (de)prescribing of these drugs (e.g. a clinical decision tree for deprescribing diuretics in older adults who have fallen).Keywords
This publication has 115 references indexed in Scilit:
- Morbus Diureticus in the Elderly: Epidemic Overuse of a Widely Applied Group of DrugsJournal of the American Medical Directors Association, 2013
- Diuretic initiation and the acute risk of hip fractureOsteoporosis International, 2012
- Targeting Outpatient Drug SafetyDrug Safety, 2012
- Societal Consequences of Falls in the Older Population: Injuries, Healthcare Costs, and Long-Term Reduced Quality of LifeJournal of Trauma: Injury, Infection & Critical Care, 2011
- Risk Factors for Falls in Community-dwelling Older PeopleEpidemiology, 2010
- Loop Diuretic Use and Rates of Hip Bone Loss and Risk of Falls and Fractures in Older WomenJournal of the American Geriatrics Society, 2009
- Medication Withdrawal Trials in People Aged 65 Years and OlderDrugs & Aging, 2008
- Postural Blood Pressure Changes and Orthostatic Hypotension in the Elderly PatientDrugs & Aging, 2005
- Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1994
- THE EFFECTS OF DISCONTINUING LONG-TERM DIURETIC THERAPY IN THE ELDERLYAge and Ageing, 1977